Corvus PharmaceuticalsFRA:C17 +3.41%32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Corvus Pharmaceuticals ranks worse than 105932.1% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Corvus Pharmaceuticals EBITDA Margin % Related Terms
Corvus Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Corvus Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C17 vs JBIO, ABSI, SVRA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Corvus Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corvus Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals (FRA:C17) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Corvus Pharmaceuticals and its competitors. According to the industry distribution chart, Corvus Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry.
Is Corvus Pharmaceuticals' EBITDA Margin % too high?
Corvus Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Corvus Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corvus Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' EBITDA Margin % compare to JBIO and ABSI?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #999999 out of 944 companies for EBITDA Margin %. This places Corvus Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Corvus Pharmaceuticals' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
32GF Score
Get the complete analysis for FRA:C17
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C17 has been successfully added to your 
